leukaemia
Conditions
Interventions
Patients will be asked to provide twelve microsampling samples obtained by
finger prick (eight dried microsampling spots and four wet blood samples in
microtainer EDTA) and four plasma samples obtai
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: • Willing and able to provide informed consent; • 18 years of age or older; • Using one of the following drugs: o Imatinib o Dasatinib o Nilotinib o Gilteritinib o Midostaurin o Venetoclax
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: • Not able to sample themselves using a finger prick.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the method agreement between plasma and microsampling (DBS/VAMS). The secondary endpoints are the success rate of microsampling and the difference in SUS score between HemaXis DB 10 and Mitra Clamshell. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Success rate of microsampling: calculated by the percentage of DBS/VAMS spots that was accepted for analysis by the laboratory technician. Reasons for disapproval will be described by the laboratory technician . • SUS score: calculated by converting the questionnaire into a 0 to 100 scale score. In the SUS scale, *strongly disagree* correlates with 1 point, *disagree* with 2 points, *neutral* with 3 points, *agree* with 4 points and *strongly agree* with five points. The SUS score equals to (X + Y) x 2.5. X is the sum of the points for all odd-numbered questions minus 5. Y is 25 minus the sum of all even-numbered questions. | — |
Countries
Netherlands
Contacts
Public ContactAD Levens
Leids Universitair Medisch Centrum
Outcome results
None listed